<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02798835</url>
  </required_header>
  <id_info>
    <org_study_id>H16-01058</org_study_id>
    <nct_id>NCT02798835</nct_id>
  </id_info>
  <brief_title>Single Injection Adductor Canal Block vs Catheter for Total Knee Arthroplasty</brief_title>
  <official_title>Adductor Canal Block: Single Injection vs Catheter for Pain Management of Total Knee Arthroplasty - A Randomized, Unblinded, Non-Inferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates single injection adductor canal block (ACB) with or without
      intravenous dexamethasone and adductor canal catheter for pain management of total knee
      arthroplasty. This is a non-inferiority trial seeking to determine whether single injection
      ACB with dexamethasone is &quot;no worse&quot; than a continuous catheter.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Purpose

           To determine whether single shot adductor canal nerve blocks with intravenous
           dexamethasone are non-inferior to continuous adductor canal blockade.

        2. Hypotheses

           The use of adductor canal nerve block with intravenous dexamethasone will not be
           inferior to continuous adductor canal blockade for opioid requirements 24h post
           operatively.

           The single injection adductor canal block without dexamethasone will have the most
           opioid consumption. The dexamethasone and catheter groups will be superior to single
           injection alone in terms of 12 and 48h opioid consumption, length of stay, anti-emetic
           usage, pain score and quality of recovery score.

        3. Justification

           Total knee arthroplasty is a very commonly performed operation in North America, with a
           high propensity for postoperative pain. Inadequate analgesia limits functional recovery
           and leads to delays in hospital discharge, as a result of poor mobility. Effective
           analgesia allows for earlier mobilization and improved postoperative recovery, with a
           multi-modal regime being the ideal method to achieve this.

           Currently a multi-modal regime is provided to patients: intraoperatively with a
           neuraxial technique (spinal anesthesia), along with surgeon infiltrated local anesthetic
           at the end of the operation, and then postoperatively using systemic opioids via patient
           controlled analgesia (PCA). Opioids have many side effects, including nausea and
           vomiting, sedation, respiratory depression and urinary retention. These all lead to
           delay in ambulation and recovery.

           Many centers now incorporate peripheral nerve blocks as part of the multi-modal
           analgesic regime, with continuous femoral nerve blockade being commonly used for
           analgesia. This does decrease the amount of postoperative opioid used, but has the
           downside of causing quadriceps muscle weakness leading to an increased risk of falls and
           delayed ambulation. For this reason, there has been an increase in the use of the
           adductor canal block, a nerve block of the distal femoral nerve at the mid-thigh level,
           that has been shown to preserve quadriceps function better than a femoral nerve block,
           whilst still ensuring decreased opioid use. To date, no studies have compared single
           shot adductor canal block with continuous adductor canal blockade, but both have been
           shown to be comparable to femoral nerve blockade, whilst decreasing the likelihood of
           quadriceps muscle weakness.

           Further to this, it has been shown that the addition of dexamethasone, administered via
           the intravenous or perineural route to peripheral nerve blockade, prolongs the duration
           of analgesia. Perineural administration of dexamethasone is an off label use and there
           is also a theoretical risk of neurotoxicity from dexamethasone itself. Findings to date
           indicate that the efficacy of dexamethasone administered intravenously is non-inferior
           to perineural injection. Both routes prolong the analgesic benefit of peripheral nerve
           blocks with similar reductions in opioid requirements.

           Opioid PCA is the most commonly used modality for postoperative analgesia following
           total knee arthroplasty. The information from this study will enable ascertainment of
           the best method for allowing patients good functional recovery, whilst minimizing opioid
           side effects.

        4. Objectives

           The primary aim of this study is to compare the efficacy of adductor canal nerve block,
           with and without intravenous dexamethasone, and continuous adductor canal blockade with
           a catheter to ascertain cumulative opioid consumption post-operatively. Specifically,
           the trial seeks to answer whether the adductor canal block with dexamethasone fares no
           worse (non-inferior) than a continuous catheter.

           The secondary aims are to compare the quality of anesthesia recovery using the QoR-40
           questionnaire administered at 48 hours postoperatively, pain score, length of hospital
           stay, complications of nerve blockade, incidence of catheter dislodgement and opioid
           side effects (nausea/vomiting) with the different techniques.

        5. Research Methods

           Trial Design

           This will be a randomize controlled, non-blinded, non-inferiority trial, involving
           patients having primary unilateral total knee arthroplasty. There are three arms:
           adductor canal single injection (baseline control), adductor canal single injection plus
           dexamethasone (test intervention) and adductor canal catheter (active control).

           Setting

           This will be a single-centre trial at UBC Hospital (UBCH).

           B. Randomization

           Prior to surgery, for each consented patient, a sealed unmarked opaque envelope will be
           opened to determine the modality of analgesia that the patient will receive. The
           patients will either receive an adductor canal block postoperatively, an adductor canal
           block postoperatively along with intravenous dexamethasone, or have an adductor canal
           catheter placed postoperatively for continuous adductor canal blockade.

           D. Data Collection

           Demographic data including patient age, sex, height, weight, BMI, and medications
           including analgesics, comorbidities and American Society of Anesthesia (ASA)
           classification will be determined from the anesthetic record.

           Numerical Rating Scale (NRS) pain scores from 0-10 as well as cumulative opioid
           consumption in oral morphine equivalents will be determined at set time points of 12,
           24, 48 hours. The data will be determined from the patient's pain flow sheet and
           medication administration record (MAR), which are part of the standard charting found on
           the hospital ward. Opioid data from PCA will be obtained from the hospital database
           which electronically logs usage. The patient's chart will also be used to note
           anti-emetic medication usage. At 48 hours, all participants will be provided with a
           QoR-40 questionnaire, a validated 40 item questionnaire on the quality of recovery from
           anesthesia. The time of discharge will be recorded from the hospital data base.

           Complications from adductor canal catheters will be recorded, such as catheter
           dislodgement and site infection. For patients unable to complete the study, the reason
           will be noted and data will be included in an intention to treat analysis.

           E. Statistical Analysis

           Sample Size:

           The investigators do not have institutional data of standard deviation (SD) of morphine
           equivalent consumption for primary total knee arthroplasty. Based on previous studies,
           the standard deviation of morphine equivalent consumption at 24h is estimated to be 20
           mg IV. We consider a reduction of 10 mg to be clinically relevant at this time point and
           therefore set it as the non-inferiority margin. Using the following online calculator:
           https://www.sealedenvelope.com/power/continuous-noninferior/ based on a power of 80% and
           significance level of 5%, the number of patients required per group is 50. The aim is to
           recruit 60 patients per group to account for potential drop outs.

        6. Data Analysis: Categorical data will be analysed with chi-squared tests. Numeric
           variables will be compared with independent T-tests if distributions were normal. If
           Kolmogorov-Smirnoff test for normality of distribution was significant non-parametric
           Mann Whitney U tests will be utilized. Statistical significance will be assumed if P
           &lt;0.05.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative 24 hour oral morphine equivalent consumption</measure>
    <time_frame>24 hours (Day 1)</time_frame>
    <description>Post-operative analgesia at 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative 12 hour oral morphine equivalent consumption</measure>
    <time_frame>12 hours (Day 0)</time_frame>
    <description>Post-operative analgesia at 12 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative 48 hour oral morphine equivalent consumption</measure>
    <time_frame>48 hours (Day 2)</time_frame>
    <description>Post-operative analgesia at 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Score</measure>
    <time_frame>12, 24 and 48 hours</time_frame>
    <description>Patient satisfaction using NRS pain scale 0 (no pain) to 10 (worst pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of recovery (QoR-40)</measure>
    <time_frame>48 hours (Day 2)</time_frame>
    <description>Quality of recovery measured using the QoR-40 at 48 hours postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>From surgical date until hospital discharge, up to 3 weeks</time_frame>
    <description>Time to hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea/Vomiting</measure>
    <time_frame>0 to 48 hours</time_frame>
    <description>Side effect of narcotics - incidence of anti-emetic use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first use of PCA</measure>
    <time_frame>0 to 48 hours</time_frame>
    <description>from time zero to first press of PCA button</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adductor canal block complications</measure>
    <time_frame>From time of catheter insertion until catheter removal, up to Day2/48 hours</time_frame>
    <description>Incidence of catheter dislodgement or site infection</description>
  </other_outcome>
  <other_outcome>
    <measure>Nerve block complications</measure>
    <time_frame>0 to 48 hours</time_frame>
    <description>Nerve block complications at any time point during study</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Total Knee Arthroplasty</condition>
  <arm_group>
    <arm_group_label>Adductor Canal block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Postoperatively in the PACU, this group will receive 20ml 0.5% ropivacaine for their ACB.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adductor canal block with dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Postoperatively in the PACU, this group will receive 20ml 0.5% ropivacaine for their ACB along with 8mg IV dexamethasone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adductor canal catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Postoperatively in the PACU, this group will receive 20ml 0.5% ropivacaine for their adductor canal block and have a catheter placed in the adductor canal at the mid-thigh. 0.2% ropivacaine at 5ml/hr will be run for 48 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adductor canal block</intervention_name>
    <description>Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine in the adductor canal in PACU.</description>
    <arm_group_label>Adductor Canal block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adductor canal block with dexamethasone</intervention_name>
    <description>Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine in the adductor canal along with 8mg dexamethasone IV in PACU.</description>
    <arm_group_label>Adductor canal block with dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adductor canal catheter</intervention_name>
    <description>Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine and a catheter placed in PACU, with a continuous infusion of 0.2% ropivacaine started.</description>
    <arm_group_label>Adductor canal catheter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Used in spinal anesthetic</description>
    <arm_group_label>Adductor Canal block</arm_group_label>
    <arm_group_label>Adductor canal block with dexamethasone</arm_group_label>
    <arm_group_label>Adductor canal catheter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>May or may not be used in spinal anesthetic</description>
    <arm_group_label>Adductor Canal block</arm_group_label>
    <arm_group_label>Adductor canal block with dexamethasone</arm_group_label>
    <arm_group_label>Adductor canal catheter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine 0.5% Injectable Solution</intervention_name>
    <description>Local anesthetic to be used by surgeon as local infiltration and by anesthesiologist in adductor canal block.</description>
    <arm_group_label>Adductor Canal block</arm_group_label>
    <arm_group_label>Adductor canal block with dexamethasone</arm_group_label>
    <arm_group_label>Adductor canal catheter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>To be given intravenously at time of nerve block to one of the study arms.</description>
    <arm_group_label>Adductor canal block with dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over or equal to the age of 18 years old who can understand the study
             protocol and are able to give consent

          -  Patients with an American Society of Anaesthesiology (ASA) classification 1 to 3

          -  Patients must have a preoperative oral 24 hour opioid consumption of less than or
             equal to 30 mg morphine equivalents

          -  Patients must be able to understand and be able to use patient controlled analgesia

          -  Patients must be undergoing a primary total knee arthroplasty with neuraxial
             anesthesia

        Exclusion Criteria:

          -  Patients with a contraindication to neuraxial and/or regional anaesthesia

          -  Patients with an allergy to local anaesthetics

          -  Patients who have chronic pain not related to their knee joint

          -  Patients with chronic opioid use (daily or almost daily use &gt;3 months)

          -  Patients with contraindications to dexamethasone (allergy, infection, Insulin
             dependent Diabetes Mellitus)

          -  Patients with pre-existing neuropathy

          -  Patients with hepatic failure

          -  Patients with renal failure with eGFR&lt;60

          -  Patients with allergy to ketorolac or NSAIDs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <reference>
    <citation>Perlas A, Kirkham KR, Billing R, Tse C, Brull R, Gandhi R, Chan VW. The impact of analgesic modality on early ambulation following total knee arthroplasty. Reg Anesth Pain Med. 2013 Jul-Aug;38(4):334-9. doi: 10.1097/AAP.0b013e318296b6a0.</citation>
    <PMID>23759708</PMID>
  </reference>
  <reference>
    <citation>Kim DH, Lin Y, Goytizolo EA, Kahn RL, Maalouf DB, Manohar A, Patt ML, Goon AK, Lee YY, Ma Y, Yadeau JT. Adductor canal block versus femoral nerve block for total knee arthroplasty: a prospective, randomized, controlled trial. Anesthesiology. 2014 Mar;120(3):540-50. doi: 10.1097/ALN.0000000000000119.</citation>
    <PMID>24401769</PMID>
  </reference>
  <reference>
    <citation>Allen HW, Liu SS, Ware PD, Nairn CS, Owens BD. Peripheral nerve blocks improve analgesia after total knee replacement surgery. Anesth Analg. 1998 Jul;87(1):93-7.</citation>
    <PMID>9661553</PMID>
  </reference>
  <reference>
    <citation>Charous MT, Madison SJ, Suresh PJ, Sandhu NS, Loland VJ, Mariano ER, Donohue MC, Dutton PH, Ferguson EJ, Ilfeld BM. Continuous femoral nerve blocks: varying local anesthetic delivery method (bolus versus basal) to minimize quadriceps motor block while maintaining sensory block. Anesthesiology. 2011 Oct;115(4):774-81. doi: 10.1097/ALN.0b013e3182124dc6.</citation>
    <PMID>21394001</PMID>
  </reference>
  <reference>
    <citation>Jaeger P, Nielsen ZJ, Henningsen MH, Hilsted KL, Mathiesen O, Dahl JB. Adductor canal block versus femoral nerve block and quadriceps strength: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. Anesthesiology. 2013 Feb;118(2):409-15. doi: 10.1097/ALN.0b013e318279fa0b.</citation>
    <PMID>23241723</PMID>
  </reference>
  <reference>
    <citation>Jenstrup MT, JÃ¦ger P, Lund J, Fomsgaard JS, Bache S, Mathiesen O, Larsen TK, Dahl JB. Effects of adductor-canal-blockade on pain and ambulation after total knee arthroplasty: a randomized study. Acta Anaesthesiol Scand. 2012 Mar;56(3):357-64. doi: 10.1111/j.1399-6576.2011.02621.x. Epub 2012 Jan 4.</citation>
    <PMID>22221014</PMID>
  </reference>
  <reference>
    <citation>Abdallah FW, Johnson J, Chan V, Murgatroyd H, Ghafari M, Ami N, Jin R, Brull R. Intravenous dexamethasone and perineural dexamethasone similarly prolong the duration of analgesia after supraclavicular brachial plexus block: a randomized, triple-arm, double-blind, placebo-controlled trial. Reg Anesth Pain Med. 2015 Mar-Apr;40(2):125-32. doi: 10.1097/AAP.0000000000000210. Erratum in: Reg Anesth Pain Med. 2015 Jul-Aug;40(4):398.</citation>
    <PMID>25629321</PMID>
  </reference>
  <reference>
    <citation>Rahangdale R, Kendall MC, McCarthy RJ, Tureanu L, Doty R Jr, Weingart A, De Oliveira GS Jr. The effects of perineural versus intravenous dexamethasone on sciatic nerve blockade outcomes: a randomized, double-blind, placebo-controlled study. Anesth Analg. 2014 May;118(5):1113-9. doi: 10.1213/ANE.0000000000000137.</citation>
    <PMID>24686045</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2016</study_first_submitted>
  <study_first_submitted_qc>June 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2016</study_first_posted>
  <last_update_submitted>June 14, 2017</last_update_submitted>
  <last_update_submitted_qc>June 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Steven Lee</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

